JNK signalling: a possible target to prevent neurodegeneration
Related Experiment Video
Updated: Jul 14, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
Tiziana Borsello1, Gianluigi Forloni
1Biol. Neurodeg. Disorders Lab., Istituto di Ricerche Farmacologiche, Mario Negri, Milano, Italy. borsello@marionegri.it
Abstract:
The c-Jun N-terminal kinases (JNK) belong to the subfamily of mitogen-activated protein kinase (MAPK). JNK is an important transducing enzyme that is involved in many facets of cellular regulation including gene expression, cell proliferation and programmed cell death. The activation of JNK pathways is critical for naturally occurring cell death during development as well as for pathological death associated with neurodegenerative diseases. Initial research concentrated on defining the components and organization of JNK signalling cascades, but more recent studies see JNK as a target to prevent cell death. Several in vitro and in vivo studies have reported alterations of JNK pathways potentially associated with neuronal death in Parkinson's and Alzheimer's disease. So efforts are now aimed at developing chemical inhibitors of this pathway. These have proved effective in vivo, reducing brain damage and some of the symptoms of arthritis in animal models. An alternative cell penetrating peptide approach is now available, with the identification of the JNK permeable peptide inhibitor, which modifies JNK action rather than activation, preventing neuronal death with unprecedented specificity and efficacy in several experimental conditions, including two animal models of ischemia. In this review we examine in detail the role of JNK in neurodegeneration, particularly in Alzheimer's and Parkinson's disease. The possibility of intervention on the JNK pathway as a therapeutic approach is also illustrated.
Insights
c-Jun N-terminal kinases (JNK) are key in cell death, impacting neurodegenerative diseases like Alzheimer's and Parkinson's. Targeting JNK pathways offers a promising therapeutic strategy to prevent neuronal death and brain damage.
Area of Science:
- Cellular Biology
- Neuroscience
- Molecular Biology
Background:
- c-Jun N-terminal kinases (JNK), a mitogen-activated protein kinase (MAPK) subfamily, regulate crucial cellular processes like gene expression, proliferation, and programmed cell death.
- JNK pathway activation is vital for both developmental and pathological cell death, particularly in neurodegenerative conditions.
Purpose of the Study:
- To review the role of JNK in neurodegeneration, focusing on Alzheimer's and Parkinson's disease.
- To explore therapeutic interventions targeting the JNK pathway for neuroprotection.
Main Methods:
- Review of in vitro and in vivo studies on JNK pathway alterations in neurodegenerative diseases.
- Analysis of therapeutic strategies including chemical inhibitors and cell-penetrating peptide inhibitors of JNK.
Main Results:
- JNK pathway alterations are implicated in neuronal death in Parkinson's and Alzheimer's disease.
- Chemical and peptide-based JNK inhibitors demonstrate efficacy in reducing brain damage and symptoms in animal models.
- JNK-permeable peptide inhibitors show high specificity and efficacy in preventing neuronal death in experimental models, including ischemia.
Conclusions:
- The JNK pathway is a significant factor in neurodegeneration.
- Modulating JNK activity presents a viable therapeutic avenue for treating neurodegenerative diseases.
- Targeting JNK offers a promising strategy for neuroprotection and mitigating disease progression.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
The JAK-STAT Signaling Pathway
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...